ATE370967T1 - Polyspezifische bindemoleküle und deren verwendung - Google Patents

Polyspezifische bindemoleküle und deren verwendung

Info

Publication number
ATE370967T1
ATE370967T1 AT99970601T AT99970601T ATE370967T1 AT E370967 T1 ATE370967 T1 AT E370967T1 AT 99970601 T AT99970601 T AT 99970601T AT 99970601 T AT99970601 T AT 99970601T AT E370967 T1 ATE370967 T1 AT E370967T1
Authority
AT
Austria
Prior art keywords
binding molecules
polyspecific binding
chain
molecules
polyspecific
Prior art date
Application number
AT99970601T
Other languages
English (en)
Inventor
Jon Weidanz
Kimberlyn Card
Linda Sherman
Norman Klinman
Hing Wong
Original Assignee
Altor Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corp filed Critical Altor Bioscience Corp
Application granted granted Critical
Publication of ATE370967T1 publication Critical patent/ATE370967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99970601T 1998-10-21 1999-10-21 Polyspezifische bindemoleküle und deren verwendung ATE370967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10516498P 1998-10-21 1998-10-21

Publications (1)

Publication Number Publication Date
ATE370967T1 true ATE370967T1 (de) 2007-09-15

Family

ID=22304401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970601T ATE370967T1 (de) 1998-10-21 1999-10-21 Polyspezifische bindemoleküle und deren verwendung

Country Status (9)

Country Link
US (3) US6534633B1 (de)
EP (1) EP1124568B1 (de)
JP (1) JP4467188B2 (de)
AT (1) ATE370967T1 (de)
AU (1) AU1218000A (de)
DE (1) DE69936927T2 (de)
DK (1) DK1124568T3 (de)
ES (1) ES2293748T3 (de)
WO (1) WO2000023087A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322228B1 (de) * 2000-06-05 2018-01-10 Altor BioScience Corporation T-Zell-Rezeptor Fusionsproteine und Konjugate und Verfahren zu deren Verwendung
WO2004018619A2 (en) 2001-06-05 2004-03-04 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
JP2006523437A (ja) * 2002-12-03 2006-10-19 アヴィデックス リミテッド レセプター複合体
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
KR101131297B1 (ko) * 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
US7964380B2 (en) * 2005-01-21 2011-06-21 Argylia Technologies Nanoparticles for manipulation of biopolymers and methods of thereof
GB0507046D0 (en) * 2005-04-06 2005-05-11 Celltech R&D Ltd Primers
EP1945771A1 (de) * 2005-10-28 2008-07-23 Novo Nordisk A/S Effektorlymphozyten und zielzellen bindende fusionsproteine
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
WO2008003100A2 (en) * 2006-06-29 2008-01-03 Xiaolian Gao Make and use of surface molecules of varied densities
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2009117117A1 (en) * 2008-03-19 2009-09-24 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use there of
WO2009151514A1 (en) * 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
MX2011000009A (es) * 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
DK2370561T3 (da) * 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
EP2258719A1 (de) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Mehrfachziel-T-Zellen-Rezeptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
EP2580349A2 (de) * 2010-06-08 2013-04-17 EMD Millipore Corporation Verfahren für den nachweis von rückständen von bei der reinigung von biomolekülen verwendeten polymeren
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
CA2851270C (en) 2011-10-05 2023-03-14 The Rockefeller University Dimeric bacteriophage lysins
KR101963230B1 (ko) 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP2802356A1 (de) 2012-01-13 2014-11-19 Apo-T B.V. Aberrante zelleingeschränkte immunglobuline mit einem toxischen teil
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
EP2934532B1 (de) 2012-12-20 2019-10-23 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
JP6476182B2 (ja) 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド ｇｐ１００特異的ＴＣＲ－抗ＣＤ３ ｓｃＦｖ融合タンパク質の投薬レジメン
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (de) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteine, die her2, nkg2d und cd16 binden
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
WO2018166589A1 (en) 2017-03-15 2018-09-20 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
CA3070468A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
EP3941938A1 (de) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. Für das b-zell-reifungsantigen spezifische t-zell-rezeptoren zur behandlung von krebs
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (de) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc Verfahren zur behandlung von krebs mit multispezifischen bindungsproteinen zur bindung von nkg2d, cd16 und einem tumorassoziierten antigen
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
JP2026501516A (ja) * 2023-01-05 2026-01-16 アンヘレス セラピューティクス インコーポレイテッド 遺伝子導入および合成および免疫受容体の活性を制御するための方法および組成物
GB202320012D0 (en) * 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
TW202617750A (zh) * 2024-07-10 2026-05-01 美商安吉利斯治療學公司 包含表位與多肽的組成物及方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500329A (ja) * 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
KR930701620A (ko) 1990-08-09 1993-06-12 프레드릭 에이. 란길레 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
JPH11507843A (ja) * 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
CA2305630C (en) * 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins

Also Published As

Publication number Publication date
ES2293748T3 (es) 2008-03-16
US20120230995A1 (en) 2012-09-13
US20030171552A1 (en) 2003-09-11
EP1124568A4 (de) 2003-08-27
DK1124568T3 (da) 2008-01-02
DE69936927D1 (de) 2007-10-04
AU1218000A (en) 2000-05-08
US8105830B2 (en) 2012-01-31
EP1124568B1 (de) 2007-08-22
DE69936927T2 (de) 2008-05-15
JP4467188B2 (ja) 2010-05-26
EP1124568A1 (de) 2001-08-22
JP2004537952A (ja) 2004-12-24
US6534633B1 (en) 2003-03-18
WO2000023087A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
DE69936927D1 (de) Polyspezifische bindemoleküle und deren verwendung
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
ATE276275T1 (de) Mhc-komplexe und ihre verwendungen
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
NO961706D0 (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
BR0209933A (pt) Uso de um ativador da transmembrana e modulador de cálcio, e proteìna de fusão de (taci) - imunoglobulina interatuadora do ligando da ciclofilina, proteìna de fusão, molécula de ácido nucleico, e, composição farmacêutica
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
DE69942981D1 (de) Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
DK1479696T3 (da) Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos
CY1115295T1 (el) Συνθεση για την θεραπεια παθολογιας συνδεομενης με msrv/herv-w
DE69738454D1 (de) Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
AR029642A1 (es) Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
WO2003106649A3 (en) CONJUGATE TEST AND USES THEREOF
NO20053304L (no) NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse
NO20022441L (no) Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
DK1121594T3 (da) Fremgangsmåder til identifikation af hot-spot remanenser af bindende proteiner og små forbindelser som binder til samme
EP1017716A4 (de) Car-rezeptoren, verwandte moleküle und methoden
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
EA200400384A1 (ru) Растворимый рецептор т-клетки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1124568

Country of ref document: EP